quinazolines has been researched along with 1,2,5,8-tetrahydroxy anthraquinone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y | 1 |
| Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y | 1 |
2 other study(ies) available for quinazolines and 1,2,5,8-tetrahydroxy anthraquinone
| Article | Year |
|---|---|
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2016 |
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Topics: Adenocarcinoma of Lung; Anthraquinones; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |